This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
10 - 12 June, 2025
Congress CenterBasel Switzerland

LIVE Virtual Training Courses

Antibody Engineering & Therapeutics Series is offering not just one but two training courses focusing on bringing your team up-to-speed quickly on fundamentals of a) Antibody Engineering and b) Bioconjugates and ADCs.

Whether purchased separately as a stand-alone or as part of the main conference experience, these popular courses will provide your team with the foundation to better improve communications and understanding of these key areas.

LIVE Virtual Training Course: Introduction to Bioconjugates and ADC Design and Development

15-17 June 2021
3:00 pm - 5:30 pm BST (British Summer Time) | 10:00 am - 12:30 pm EST | 7:00 am - 9:30 am PST

2.5 hours per day

Complex biomolecules and assemblies of biomolecules are being developed to treat diverse indications. These include Antibody-Drug Conjugates, various vaccine formats and nanoparticles. A major challenge is that the best or only method to produce one component (e.g. an antibody for an ADC) is not compatible with the production of another component (e.g. the toxic payload of the ADC produced in a microbe or via chemical synthesis). This course surveys and evaluates the key aspects of bioconjugate/ADC design, why each piece is important and how each can synergize to make an optimized product.

  • Bioconjugation. From a few simple chemical conjugation methods originally available, we have extended the chemistries and also added enzymatic catalysts to conjugate biomolecules.
  • Specialized linker designs. While some kind of linker is required, they can be designed to enhance properties of the conjugates, depending upon the “payload” or moiety to be linked together, sometimes incorporating a built-in release mechanism.
  • Effect of payload. Selecting a payload for an ADC or nanoparticle to minimize off-target side-effects.
  • Selecting a target for and ADC or nanoparticle.


Scientists and managers involved in the development of therapeutic bioconjugates – ADCs, nanoparticles, conjugate vaccines – in pharma and biotech companies.


The course offers a comprehensive overview of the current state-of-the-art approaches available for ADCs, nanoparticles and conjugate vaccines, and provides an introductory framework so participants can rapidly identify issues and solutions in their specific bioconjugate projects. It is aimed to provide even beginners with explanations of the nomenclature and science. The teams involved in bioconjugate development need both chemists and biologists to work together effectively. The course provides opportunity to better understand both aspects of the science and thus enhance communication within your team.

  • Gain an overview of the key aspects and design parameters for diverse bioconjugates.
  • Scientific terms and acronyms relating to ADCs and bioconjugates will be defined and explained.
  • Current state-of-the-art solutions for the various challenges faced in developing an ADC or bioconjugate.
  • Specific challenges for particular product formats – vaccines, ADCs, nanoparticles, etc.
  • Better understand what the others in your bioconjugate team are working to accomplish.


  • Antibody and Protein Structure
  • ADCs
  • Nanoparticle designs
  • Payload decisions
  • Conjugate vaccine components: antigens, adjuvants, etc.,
  • Bioconjugation by chemistry and enzyme
  • Linker designs for release or stability
  • Linkers and solubility


1-3 June 2021
3:00 pm - 5:30 pm BST (British Summer Time) | 10:00 am - 12:30 pm EST | 7:00 am - 9:30 am PST

Whether you need a refresher on antibody engineering concepts and applications, are new to the field or have new responsibilities in antibody/protein engineering & therapeutics-related department, you will find this popular course extremely helpful!

Delivered over 3 days in easily digestible 2.5 hour modules, the knowledge gained from this comprehensive training course is invaluable.

Want to train your entire team? Contact Jessica Purnell for information about affordable company license options at or call: +44 (0)20 7551 9521.

Course Overview

Today’s wealth of knowledge of protein structures will be reviewed along with the genetics of diversity generation of antibodies, to give insights into the best strategies for improving protein function. There is particular emphasis on the choice of a functional assay to monitor effectively the changes in a desired property, and the use of functional enrichment steps where a library approach is employed. Not only is amino acid sequence amenable to may also be engineered. The course will focus on the engineering and enhancement of antibodies and antibody-like scaffolds. Examples will include work on antibody by diverse approaches and the adaptation to generate Chimeric Antibody Receptor (CAR) constructs will be discussed. Expression platforms for producing antibodies for testing and for manufacture will also be covered. A background in biochemistry and molecular biology is useful, as the course is designed to progress rapidly from simple to advanced concepts.

Topics Include

  • Functions amenable to engineering: Affinity, specificity, stability, solubility, immunogenicity
  • The measure of success: functional assays
  • Engineering by design
  • Engineering by random mutation
  • Immunogenicity engineering
  • Antibody-drug conjugates (ADCs)
  • CAR-T strategies
  • Designed libraries
  • Expression of antibodies and fragments for discovery
  • Display technologies
  • Improving manufacturing by protein engineering methods
  • Glycosylation engineering – function and homogeneity